'UK Government Snubs GSK in Favor of Pfizer's Rival RSV Shot' - Bloomberg
Portfolio Pulse from Benzinga Newsdesk
GSK Plc has lost a contract to supply its RSV vaccine to the UK government, which has chosen Pfizer Inc.'s rival RSV shot instead. This is a significant setback for GSK.
June 24, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer Inc. has secured a contract to supply its RSV vaccine to the UK government, beating out GSK Plc. This is a significant win for Pfizer.
Winning a major contract can positively impact Pfizer's revenue and market perception, especially since the RSV vaccine is considered a blockbuster product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
GSK Plc has lost a contract to supply its RSV vaccine to the UK government, which has chosen Pfizer Inc.'s rival RSV shot instead. This is a significant setback for GSK.
Losing a major contract to a competitor can negatively impact GSK's revenue and market perception, especially since the RSV vaccine is considered a blockbuster product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100